WO2000027414A3 - Inhibition of the formation of vascular hyperpermeability - Google Patents

Inhibition of the formation of vascular hyperpermeability Download PDF

Info

Publication number
WO2000027414A3
WO2000027414A3 PCT/US1999/025903 US9925903W WO0027414A3 WO 2000027414 A3 WO2000027414 A3 WO 2000027414A3 US 9925903 W US9925903 W US 9925903W WO 0027414 A3 WO0027414 A3 WO 0027414A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
tyrosine kinase
effusions
edema
edematous
Prior art date
Application number
PCT/US1999/025903
Other languages
French (fr)
Other versions
WO2000027414A2 (en
Inventor
Lee D Arnold
Peter F Bousquet
Original Assignee
Basf Ag
Lee D Arnold
Peter F Bousquet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002347916A priority Critical patent/CA2347916A1/en
Application filed by Basf Ag, Lee D Arnold, Peter F Bousquet filed Critical Basf Ag
Priority to IL14258399A priority patent/IL142583A0/en
Priority to KR1020017005724A priority patent/KR20010080952A/en
Priority to BR9915139-1A priority patent/BR9915139A/en
Priority to HU0104302A priority patent/HUP0104302A3/en
Priority to SK505-2001A priority patent/SK5052001A3/en
Priority to EP99962685A priority patent/EP1126842A2/en
Priority to AU19080/00A priority patent/AU1908000A/en
Priority to JP2000580643A priority patent/JP2002529421A/en
Publication of WO2000027414A2 publication Critical patent/WO2000027414A2/en
Publication of WO2000027414A3 publication Critical patent/WO2000027414A3/en
Priority to BG105476A priority patent/BG105476A/en
Priority to NO20012218A priority patent/NO20012218L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes

Abstract

Vascular hyperpermeability and the subsequent events such as macular edema, retinoblastoma, ocular ischemia, ocular inflammatory disease or infection, choroidal melanoma, edematous side-effects induced by iron chelation therapy, pulmonary edema, myocardial infarction, rheumatoid diseases, anaphylaxis, allergies, hypersensitive reactions, cerebral edema, brain tumor fluid-filled cysts, communicating hydrocephalus, carpal tunnel syndrome, organ damage resulting from a burn, irritation or infection, erythema multiforme, edematous macules and other disorders, brain tumors, tumor effusions, lung or breast carcinomas, ascites, pleural effusions, pericardial effusions, high altitude 'sickness', radioanaphylaxis, radiodermatitis, glaucoma, conjunctivitis, choroidal melanoma, adult respiratory distress syndrome, asthma, bronchitis, ovarian hyperstimulation syndrome, polycystic ovary syndrome, menstrual swelling, menstrual cramps, stroke, head trauma, cerebral infarct or occlusion, hyotension, ulcerations, sprains, fractures, effusions associated with synovitis, diabetic complications, hyperviscosity syndrome, liver cirrhosis, microalbuminuria, proteinuria, oliguria, electrolyte imbalance, nephrotic syndrome, exudates, fibroses, keloid, can be inhibited by the administration of a compound that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. The preferred compound 4,5-dihydro-3-pyridin-4-yl-1(2)H-benzo[g]indazole selectively inhibits the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGE tyrosine kinase receptor.
PCT/US1999/025903 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability WO2000027414A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SK505-2001A SK5052001A3 (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
IL14258399A IL142583A0 (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
KR1020017005724A KR20010080952A (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
BR9915139-1A BR9915139A (en) 1998-11-06 1999-11-03 Method of inhibiting vascular hyperpermeability, and of inhibiting a physiological process or state in an individual
HU0104302A HUP0104302A3 (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
CA002347916A CA2347916A1 (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
EP99962685A EP1126842A2 (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
AU19080/00A AU1908000A (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability
JP2000580643A JP2002529421A (en) 1998-11-06 1999-11-03 Methods for inhibiting vascular hyperpermeability
BG105476A BG105476A (en) 1998-11-06 2001-04-25 Method for the inhibition of vascular hyperpermeability
NO20012218A NO20012218L (en) 1998-11-06 2001-05-04 Inhibition of vascular hyperpermeability formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10746298P 1998-11-06 1998-11-06
US60/107,462 1998-11-06

Publications (2)

Publication Number Publication Date
WO2000027414A2 WO2000027414A2 (en) 2000-05-18
WO2000027414A3 true WO2000027414A3 (en) 2000-09-08

Family

ID=22316735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025903 WO2000027414A2 (en) 1998-11-06 1999-11-03 Inhibition of the formation of vascular hyperpermeability

Country Status (19)

Country Link
EP (1) EP1126842A2 (en)
JP (1) JP2002529421A (en)
KR (1) KR20010080952A (en)
CN (1) CN1342077A (en)
AR (1) AR023912A1 (en)
AU (1) AU1908000A (en)
BG (1) BG105476A (en)
BR (1) BR9915139A (en)
CA (1) CA2347916A1 (en)
CO (1) CO5150183A1 (en)
CZ (1) CZ20011564A3 (en)
HU (1) HUP0104302A3 (en)
ID (1) ID29063A (en)
IL (1) IL142583A0 (en)
NO (1) NO20012218L (en)
PL (1) PL348163A1 (en)
SK (1) SK5052001A3 (en)
TR (1) TR200102278T2 (en)
WO (1) WO2000027414A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE553782T1 (en) * 1999-12-22 2012-05-15 Scripps Research Inst PHARMACEUTICAL COMPOSITIONS CONTAINING SRC AND/OR YES AND THEIR USE
DE10021246A1 (en) * 2000-04-25 2001-10-31 Schering Ag New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
WO2003018057A1 (en) * 2001-07-26 2003-03-06 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
PT2949658T (en) 2003-03-03 2018-10-18 Bracco Suisse Sa Peptides that specifically bind hgf receptor (cmet) and uses thereof
DE602004007382T2 (en) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven DIARYL UREAS FOR PDGFR MEDIATED DISEASES
DE602004010407T2 (en) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
RU2542471C2 (en) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Improved methods and compositions for wound healing
US8546349B2 (en) 2010-07-28 2013-10-01 Thermo Fisher Scientific Biosciences Inc. siRNA targeting VEGFA and methods for treatment in vivo
KR101565886B1 (en) 2013-10-23 2015-11-05 전남대학교산학협력단 Method and Kit for Diagnosting of Ovarian Hyperstimulation Syndrome
CN114010788A (en) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 Channel modulators
CN106381330A (en) * 2016-08-30 2017-02-08 张建华 Primer and kit for detecting susceptibility of communicating hydrocephalus
EP3770172A4 (en) * 2018-03-19 2022-08-31 Pharmabcine Inc. Anti-vegfr-2 antibody
CN109718253B (en) * 2019-01-16 2021-09-24 中国人民解放军总医院 Use of bacteria capable of metabolizing to produce histamine for preventing or treating altitude sickness

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2317716A1 (en) * 1971-10-13 1974-05-02 Sandoz Ag NEW ORGANIC COMPOUNDS AND PROCEDURES FOR THEIR PRODUCTION
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843664A (en) * 1973-02-20 1974-10-22 Sandoz Ag Substituted naphtho pyrazoles
WO1997015662A2 (en) * 1995-10-26 1997-05-01 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
FR2742662A1 (en) * 1995-12-21 1997-06-27 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS
WO1997044453A1 (en) * 1996-05-07 1997-11-27 Genentech, Inc. Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1998011223A1 (en) * 1996-09-11 1998-03-19 Schering Aktiengesellschaft Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr)
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
WO1999055335A1 (en) * 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932430A (en) * 1971-10-13 1976-01-13 Sandoz, Inc. Substituted indeno, naphtho and cyclohepta pyrazoles
DE2317716A1 (en) * 1971-10-13 1974-05-02 Sandoz Ag NEW ORGANIC COMPOUNDS AND PROCEDURES FOR THEIR PRODUCTION
US3843664A (en) * 1973-02-20 1974-10-22 Sandoz Ag Substituted naphtho pyrazoles
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
WO1997015662A2 (en) * 1995-10-26 1997-05-01 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
FR2742662A1 (en) * 1995-12-21 1997-06-27 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS
WO1997044453A1 (en) * 1996-05-07 1997-11-27 Genentech, Inc. Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
WO1998011223A1 (en) * 1996-09-11 1998-03-19 Schering Aktiengesellschaft Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr)
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
WO1999055335A1 (en) * 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Also Published As

Publication number Publication date
ID29063A (en) 2001-07-26
CN1342077A (en) 2002-03-27
EP1126842A2 (en) 2001-08-29
AU1908000A (en) 2000-05-29
CZ20011564A3 (en) 2002-04-17
NO20012218L (en) 2001-06-18
JP2002529421A (en) 2002-09-10
AR023912A1 (en) 2002-09-04
IL142583A0 (en) 2002-03-10
CO5150183A1 (en) 2002-04-29
BR9915139A (en) 2001-08-07
TR200102278T2 (en) 2001-12-21
PL348163A1 (en) 2002-05-06
HUP0104302A3 (en) 2002-11-28
HUP0104302A2 (en) 2002-03-28
CA2347916A1 (en) 2000-05-18
KR20010080952A (en) 2001-08-25
WO2000027414A2 (en) 2000-05-18
NO20012218D0 (en) 2001-05-04
BG105476A (en) 2002-02-28
SK5052001A3 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
WO2000027414A3 (en) Inhibition of the formation of vascular hyperpermeability
US6664269B2 (en) Isoquinolinone derivatives
US7151102B2 (en) Phthalazinone derivatives
DE69636279T2 (en) TRICYCLIC AMIDS AND UREA DERIVATIVES APPLICABLE AS G-PROTEIN FUNCTION INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP0944582B1 (en) Ketobenzamides as calpain inhibitors
EP1114051B1 (en) INHIBITORS OF p38
US6300330B1 (en) Heterocycle derivatives which inhibit factor Xa
KR101130592B1 (en) Prolyl hydroxylase inhibitors and methods of use
EP1000033B1 (en) Heterocyclic derivatives which inhibit factor xa
WO1998023581A1 (en) Benzamidoaldehydes and their use as cysteine protease inhibitors
JP2002517486A (en) inhibitors of p38
EP1660439A2 (en) Aryl and heteroaryl compounds, compositions, and methods of use
HUT70485A (en) Substituted mono- and bipyridyl-methyl-pyridone derivatives and process for producing them
AU731579B2 (en) Novel alpha-hydroxy acid derivatives, their preparation and use
DE69921994T2 (en) HETEROCYCLIC COMPOUNDS WITH FACTOR XA HARDENING EFFECT
WO1998025899A1 (en) Novel heterocyclically substituted benzamides and their use in fighting diseases
EP1166785A1 (en) Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation
US5622967A (en) Quinolone carboxamide Calpain inhibitors
JP2002511459A (en) Chromanone and thiochromanone derivatives
EP1005460A1 (en) Prostaglandin endoperoxide h synthase biosynthesis inhibitors
MXPA00005190A (en) NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT.
WO1997038982A1 (en) Novel carboxylic acid derivatives, their production and use
DE60033280T2 (en) 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5- (2-METHOXY-PHENOXY) -2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
EP1027338A2 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
KR950701322A (en) New quinazolines as inhibitors of HIV reversetranscriptase as inhibitors of human immunodeficiency virus reverse transcriptase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812924.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 5052001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 142583

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2347916

Country of ref document: CA

Ref document number: 2347916

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1999 105476

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-1564

Country of ref document: CZ

Ref document number: PA/a/2001/004438

Country of ref document: MX

Ref document number: IN/PCT/2001/620/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 19080/00

Country of ref document: AU

Ref document number: 511525

Country of ref document: NZ

Ref document number: 200103611

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2000 580643

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017005724

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999962685

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/02278

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1020017005724

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999962685

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09831859

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-1564

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999962685

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017005724

Country of ref document: KR